4,0
14 feb 2017
Anonieme werknemer
Voormalige werknemer, meer dan 10 jaar
Aanbevelen
Goedkeuring directeur
Zakelijk vooruitzicht
Pluspunten
The people are great. The greatest loss for me will be not working with my colleagues anymore.
Minpunten
Pipeline falling short of expectation. Since losing the three largest contribution product patents, there has been little to make up for the loss. Diabetes portfolio is a performing poorly, Advair will soon be generic which means respiratory market will erode for Symbicort and the Oncology products -though innovative- can't make up the $$.